XML 59 R44.htm IDEA: XBRL DOCUMENT v3.19.1

Significant Accounting Policies - Collaborative Research and Development Revenue and Royalty Income from Customers (Detail)	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Schedule Of Significant Accounting Policies [Line Items]
Minimum percentage of total revenues for which customer revenue concentrations are disclosed	10.00%	10.00%	10.00%	10.00%
Ocumension Therapeutics [Member]
Schedule Of Significant Accounting Policies [Line Items]
Minimum percentage of total revenues for which customer revenue concentrations are disclosed	59.00%	0.00%	0.00%	0.00%
Alimera Sciences [Member]
Schedule Of Significant Accounting Policies [Line Items]
Minimum percentage of total revenues for which customer revenue concentrations are disclosed	21.00%	24.00%	0.00%	14.00%
Bausch Lomb [Member]
Schedule Of Significant Accounting Policies [Line Items]
Minimum percentage of total revenues for which customer revenue concentrations are disclosed	16.00%	35.00%	13.00%	77.00%
Feasibility studies [Member]
Schedule Of Significant Accounting Policies [Line Items]
Minimum percentage of total revenues for which customer revenue concentrations are disclosed	0.00%	36.00%	0.00%	0.00%
Pfizer [Member]
Schedule Of Significant Accounting Policies [Line Items]
Minimum percentage of total revenues for which customer revenue concentrations are disclosed	0.00%	0.00%	74.00%	0.00%

X

- References

No definition available.

+ Details

Name:	eypt_ScheduleOfSignificantAccountingPoliciesLineItems
Namespace Prefix:	eypt_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_AlimeraSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_BauschLombMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_FeasibilityStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=eypt_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: